This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Walter, M. F. Articles by Mason, R. P. Search for Related Content PubMed PubMed Citation Articles by Walter, M. F. Articles by Mason, R. P.

Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease

A longitudinal analysis of the PREVENT study

Mary F. Walter, PhD^*, Robert F. Jacob, PhD^*, Barrett Jeffers, PhD, Mathieu M. Ghadanfar, MD, Gregory M. Preston, PhD, Jan Buch, MD and R. Preston Mason, PhD^*,,*

^* Elucida Research, Beverly, Massachusetts
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
Pfizer Inc., New York, New York
Pfizer Central Research, Groton, Connecticut

View larger version (30K): [in a new window]   Figure 1 Quartile analysis of a lipid oxidation marker (malondialdehyde measured as thiobarbituric acid reactive substances) in patients with documented coronary artery disease. CABG = coronary artery bypass grafting; CHF = congestive heart failure; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty; RR = relative risk.